Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 1.00 |
| ▸ | F2 | P00734 | 11/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.87 |
| ▸ | PROC | P04070 | 3/20 | 0.87 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.87 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.75 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.75 |
| ▸ | F9 | P00740 | 2/20 | 0.75 |
| ▸ | KLK1 | P06870 | 1/20 | 0.75 |
| ▸ | CFH | P08603 | 1/20 | 0.74 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14318599 | 0.93 | F10 (1.00) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL8163627 | 0.87 | F10 (0.80) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL3052253 | 0.86 | F10 (1.00) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL29825652 | 0.86 | F10 (1.00) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL31067656 | 0.86 | F10 (1.00) | F10F2PRSS1PROCKLKB1 | |
| Hydrochloric Acid SCHEMBL29377504 | 0.85 | F10 (1.00) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL14176283 | 0.82 | F10 (0.80) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL5097161 | 0.82 | F10 (0.79) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL5100150 | 0.82 | F10 (0.79) | F10F2PRSS1PROCKLKB1 | |
| SCHEMBL8165499 | 0.80 | F10 (0.81) | F10F2PRSS1PROCKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285887-A1 | Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285887-A1 | Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor | F12, TFPI, PLAT | F10 11/4885F2 10/4885PRSS1 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.